Login
$MPLT
$8.17 +$0.51 (6.66%) Close

Company Executives

$MPLT Management Team

Dr. Christopher Kroeger

Co-Founder

President

Chief Executive Officer

Director

Age 57
Compensation $8.789M USD
Sex Male

Mr. Vishwas Setia

Chief Financial Officer

Age 38
Compensation $3.137M USD
Sex Male

Mr. Jonathan Gillis

Chief Accounting Officer

Chief Administrative Officer

Age 44
Compensation -
Sex Male

Mr. James Lillie

Chief Scientific Officer

Age 69
Compensation -
Sex Male

Mr. Kristopher Hanson

General Counsel

Age 53
Compensation -
Sex Male

Ms. Erin Foff

Chief Medical Officer

Age 48
Compensation $2.753M USD
Sex Female

Dr. Anatol Kreitzer

Chief Discovery Officer

Age 51
Compensation -
Sex Male
Directors
6
serving now
Independent
5 of 5
stated in the proxy; 1 not stated
Average tenure
4.2 years
from year joined
CEO also chairs the board
No
George Pavlov
Director Age On board Independent Committees Other public boards 2025 pay Source
George Pavlov
65 2019
7 years
Independent None stated None stated $9,663
Timothy Garnett
64 2023
3 years
Independent None stated Cardiol Therapeutics, Inc. $728,403
Nanna Lüneborg
50 2025
1 year
Independent
Audit Committee
BioInvent International AB Not stated
Christopher A. Kroeger
58 2018
8 years
Not stated None stated None stated Paid as CEO
Maria Walker
61 2024
2 years
Independent
Audit Committee · Chair
Five9, Inc. $895,183
Jim Trenkle Leaving at the meeting
Not stated Not stated Independent
Audit Committee
None stated Not stated
Nominated to join at the meeting
Not on the board yet; they join only if elected.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Catalyst4, Inc.
139,699,981

Purchase of Series C Preferred Stock at the Series C Milestone Closing.

With the Company Open in proxy
Novo Holdings A/S
beneficially owns more than 5% of our capital stock; Jim Trenkle, Ph.D., a director, is employed as a partner by Novo Holdings US, Inc., which provides consulting services to Novo Holdings A/S
39,999,997

Purchase of Series C Preferred Stock at the Series C Milestone Closing.

With the Company Open in proxy
Entities affiliated with NFLS Beta Limited
beneficially owned more than 5% of our capital stock prior to our IPO; Peter Bisgaard, a former director, is a managing director of NFLS Beta Limited
9,999,997

Purchase of Series C Preferred Stock at the Series C Milestone Closing.

With the Company Open in proxy
Robert C. Malenka Living Trust U/A DTD 08/21/2012
trust for which Robert Malenka, M.D., Ph.D., a member of our Board of Directors, is the sole trustee
99,998

Purchase of Series C Preferred Stock at the Series C Milestone Closing.

With the Company Open in proxy
Christopher A. Kroeger, M.D.
99,998

Purchase of Series C Preferred Stock at the Series C Milestone Closing.

With the Company Open in proxy
Catalyst4, Inc.
106,845,638

Purchase of Series D Preferred Stock in the Series D Tranche 1 closings.

With the Company Open in proxy
Forbion Growth Opportunities Fund III Coöperatief U.A.
beneficially owns more than 5% of our capital stock; Nanna Lüneborg, Ph.D., a director, is employed as a general partner by Forbion
22,818,791

Purchase of Series D Preferred Stock in the Series D Tranche 1 closings.

With the Company Open in proxy
Novo Holdings A/S
beneficially owns more than 5% of our capital stock; Jim Trenkle, Ph.D., a director, is employed as a partner by Novo Holdings US, Inc., which provides consulting services to Novo Holdings A/S
18,791,946

Purchase of Series D Preferred Stock in the Series D Tranche 1 closings.

With the Company Open in proxy
Entities affiliated with NFLS Beta Limited
beneficially owned more than 5% of our capital stock prior to our IPO; Peter Bisgaard, a former director, is a managing director of NFLS Beta Limited
11,812,080

Purchase of Series D Preferred Stock in the Series D Tranche 1 closings.

With the Company Open in proxy
spouse of Anatol Kreitzer, Ph.D.
spouse of Anatol Kreitzer, Ph.D., one of our executive officers
Between $225,000 and $275,000
November 1, 2023 to April 14, 2025

Employment with the Company, with annual salary between $225,000 and $275,000, plus RSU grants in 2024 and 2023.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support